Dr Clifford Sachs | Director, R&D Toxicology
MedImmune Inc

Dr Clifford Sachs, Director, R&D Toxicology, MedImmune Inc

Clifford Sachs is a Director R&D Toxicology in Biologics Safety Assessment group where he provides toxicology leadership to multiple programs including vaccines, antibodies for treatment of infectious disease and oncology products.  He has over 15 years of experience developing biological drugs including cell and gene therapies.  Before joining MedImmune Clifford was a Scientific Director and Janssen Fellow at Johnson and Johnson where he was the toxicology leader for Stelara during its registration for psoriasis. Clifford provided non-clinical leadership to JNJ’s cross-company cell therapy programs including a systemic cell based therapy and ocular cell based therapy/device combination product through successful IND filings through Ph 2.  He was a member of the Biotechnology Organization (BIO) BioSafe Leadership committee and past Chair of both the BioSafe Cell Therapy and Specialty Biologics Expert Working Group (SBEWG).  Previously, he held positions of increasing responsibility in toxicology groups at Biogen Idec, Abbott and Novartis Pharmaceuticals.
Clifford is certified by the American Board of Toxicology, earned his Ph.D. in Pathology from Duke University and B.S in Biology and Chemistry from Muhlenberg College.  In addition to his vocation, Clifford has an avocation: he is a part-time ski instructor.  He holds a Level 1 certification from the Professional Ski Instructors Association of America and has taught over 1000 people how to ski. 


DC Co-conference Day 2 April 4 @ 2:40

Considerations and challenges in pre-clinical safety assessment of vaccines and passive immunization strategies

  • Respiratory Syncytial Virus Infection in Adults and Pediatric populations
  • Demonstration of disease exacerbation in an animal model
  • Species selection
  • Monoclonal antibodies with half-life extension mutations

back to speakers